Dyne Therapeutics Inc (NAS:DYN)
$ 26 0.05 (0.19%) Market Cap: 2.27 Bil Enterprise Value: 1.85 Bil PE Ratio: 0 PB Ratio: 4.69 GF Score: 37/100

Dyne Therapeutics Inc at Piper Sandler Healthcare Conference Transcript

Nov 29, 2022 / 04:00PM GMT
Release Date Price: $10.79 (+1.31%)
Ted Tenthoff
Piper Sandler - Analyst

(technical difficulty) Thank you, everybody. My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler. And before I begin, I'm required to point out certain disclosures regarding the relationship between Piper and our next presenting company Dyne, which are posted at the back of the room and also at the registration desk. So Dyne is developing targeted RNA medicines to treat muscular dystrophies. Now we have DYNE-101 for type one myotonic dystrophy in the clinic and also DYNE-251 for DMD.

Here with us today is Dyne's President and CEO, my good friend, Josh Brumm, Chief Medical Officer, Dr. Wildon Farwell, and I know this is going to be the trickiest one, so I am going to apologize beforehand, but Chief Scientific Officer, Oxana Beskrovnaya.

Oxana Beskrovnaya
Dyne Therapeutics Ltd. - CSO

Thank you.

Questions & Answers

Ted Tenthoff
Piper Sandler - Analyst

Okay, you're okay, so it's all right. So thank you, guys all for being with us today. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot